TNSN97156A1 - Derives de pyrrolidinyl-et pyrrolinyl-ethylamine, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Derives de pyrrolidinyl-et pyrrolinyl-ethylamine, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
TNSN97156A1
TNSN97156A1 TNTNSN97156A TNSN97156A TNSN97156A1 TN SN97156 A1 TNSN97156 A1 TN SN97156A1 TN TNSN97156 A TNTNSN97156 A TN TNSN97156A TN SN97156 A TNSN97156 A TN SN97156A TN SN97156 A1 TNSN97156 A1 TN SN97156A1
Authority
TN
Tunisia
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
pyrrolinyl
pyrrolidinyl
Prior art date
Application number
TNTNSN97156A
Other languages
English (en)
Inventor
Ito Fumitaka
Kondo Hiroshi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN97156A1 publication Critical patent/TNSN97156A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

L' INVENTION CONCERNE UN COMPOSE DE FORMULE : (I ) DANS LAQUELLE A, Ar1, Ar2, R1, R2 ET R3 REPRESENTENT DIVERS RADICAUX ET LA LIGNE DISCONTINUE EST UNE DOUBLE LIAISON FACULTATIVE. ELLE CONCERNE EGALEMENT DES PROCEDES POUR SA PREPARATION ET DES COMPOSITIONS PHARMACEUTIQUES LE CONTENANT.UTILISATION DE CES COMPOSES ET COMPOSITIONS COMME MEDICAMENTS UTILES EN TANT QU'AGONISTES DES RECEPTEURS KAPPA
TNTNSN97156A 1996-09-18 1997-09-16 Derives de pyrrolidinyl-et pyrrolinyl-ethylamine, procede pour leur preparation et compositions pharmaceutiques les contenant TNSN97156A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IBPCT/IB96/00957 1996-09-18

Publications (1)

Publication Number Publication Date
TNSN97156A1 true TNSN97156A1 (fr) 2005-03-15

Family

ID=11004480

Family Applications (2)

Application Number Title Priority Date Filing Date
TNTNSN97092A TNSN97092A1 (ar) 1996-09-18 1997-05-27 مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.
TNTNSN97156A TNSN97156A1 (fr) 1996-09-18 1997-09-16 Derives de pyrrolidinyl-et pyrrolinyl-ethylamine, procede pour leur preparation et compositions pharmaceutiques les contenant

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TNTNSN97092A TNSN97092A1 (ar) 1996-09-18 1997-05-27 مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.

Country Status (38)

Country Link
US (7) US6201007B1 (fr)
EP (1) EP0934264B1 (fr)
JP (2) JP3195368B2 (fr)
KR (1) KR100339666B1 (fr)
CN (1) CN1237962A (fr)
AP (1) AP1016A (fr)
AR (1) AR008168A1 (fr)
AT (1) ATE249433T1 (fr)
AU (1) AU719895B2 (fr)
BG (1) BG64194B1 (fr)
BR (1) BR9711506A (fr)
CA (1) CA2266006C (fr)
CO (1) CO4920224A1 (fr)
DE (1) DE69724805T2 (fr)
DK (1) DK0934264T3 (fr)
DZ (1) DZ2309A1 (fr)
EA (1) EA001341B1 (fr)
ES (1) ES2205248T3 (fr)
HR (1) HRP970509A2 (fr)
ID (1) ID19611A (fr)
IL (3) IL147368A0 (fr)
IS (1) IS4992A (fr)
MA (1) MA26441A1 (fr)
NO (1) NO313550B1 (fr)
NZ (1) NZ334439A (fr)
OA (1) OA10996A (fr)
PA (1) PA8437201A1 (fr)
PE (1) PE109998A1 (fr)
PL (1) PL332546A1 (fr)
PT (1) PT934264E (fr)
SK (1) SK32799A3 (fr)
TN (2) TNSN97092A1 (fr)
TR (1) TR199900590T2 (fr)
TW (1) TW432047B (fr)
UA (1) UA60310C2 (fr)
WO (1) WO1998012177A1 (fr)
YU (1) YU13899A (fr)
ZA (1) ZA978358B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051587A1 (fr) 1998-04-01 1999-10-14 Ono Pharmaceutical Co., Ltd. Derives de thiophene condenses et medicaments contenant ceux-ci comme principe actif
EP0982297A3 (fr) * 1998-08-24 2001-08-01 Pfizer Products Inc. Procédé de préparation de dérivés de acide hydroxamique substitués par hydroxy-pyrrolidinyl, qui sont agonistes du récepteur opioid kappa
AU2002247886A1 (en) * 2001-04-30 2002-11-11 Pfizer Products Inc. Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists
CA2477634A1 (fr) * 2002-02-28 2003-09-04 Pfizer Products Inc. Sels de benzoate monohydrates et anhydres cristallises de (2's,3 s)-3-hydroxy-n-{2-[n-methyl-n-4-(n-pro pylamino-carbonyl)phenyl]amino-2-phenyl}-ethylpyrrolidine
AU2003269399A1 (en) * 2002-11-01 2004-05-25 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
US7423147B2 (en) * 2004-03-31 2008-09-09 Janssen Pharmaceutical, N.V. Pyridine compounds as histamine H3 modulators
US7746514B2 (en) * 2004-04-14 2010-06-29 Hung-Yi Hsu Scanner and exposure control method thereof
WO2007081978A2 (fr) * 2006-01-11 2007-07-19 Angion Biomedica Corporation Modulateurs de l'activite facteur de croissance des hepatocytes / c-met
CA2653940C (fr) 2006-05-30 2015-07-14 Janssen Pharmaceutica N.V. Composes de pyridyl amide substitues utilises comme modulateurs du recepteur de l'histamine h3
AU2007265238A1 (en) * 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Substituted benzamide modulators of the histamine H3 receptor
CA2706328C (fr) 2007-11-20 2016-04-19 Janssen Pharmaceutica N.V. Composes de cycloalkyloxy- et heterocycloalkyloxypyridine comme modulateurs du recepteur h3 de l'histamine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8801304D0 (en) * 1988-01-21 1988-02-17 Ici Plc Diamine compounds
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
WO1994018165A1 (fr) 1993-02-12 1994-08-18 Pfizer Inc. Composes de sulfonamide utilises comme agonistes des recepteurs k d'opioides
IL117440A0 (en) 1995-03-31 1996-07-23 Pfizer Pyrrolidinyl hydroxamic acid compounds and their production process

Also Published As

Publication number Publication date
ES2205248T3 (es) 2004-05-01
US6294569B2 (en) 2001-09-25
CA2266006C (fr) 2003-11-04
ZA978358B (en) 1999-03-17
NZ334439A (en) 2000-09-29
EP0934264A1 (fr) 1999-08-11
IL147367A0 (en) 2002-08-14
NO313550B1 (no) 2002-10-21
HRP970509A2 (en) 1998-08-31
SK32799A3 (en) 2000-09-12
US6310061B2 (en) 2001-10-30
MA26441A1 (fr) 2004-12-20
WO1998012177A1 (fr) 1998-03-26
YU13899A (sh) 2000-03-21
BG103239A (en) 1999-09-30
IL147368A0 (en) 2002-08-14
PL332546A1 (en) 1999-09-13
US20010011091A1 (en) 2001-08-02
BG64194B1 (bg) 2004-04-30
CN1237962A (zh) 1999-12-08
IS4992A (is) 1999-03-05
US6303602B1 (en) 2001-10-16
PE109998A1 (es) 1999-01-13
US6294557B1 (en) 2001-09-25
ID19611A (id) 1998-07-23
AP1016A (en) 2001-10-08
PT934264E (pt) 2004-01-30
US6307061B2 (en) 2001-10-23
TW432047B (en) 2001-05-01
US20010009921A1 (en) 2001-07-26
DK0934264T3 (da) 2004-01-26
EA199900209A1 (ru) 1999-10-28
BR9711506A (pt) 1999-08-24
PA8437201A1 (es) 1999-12-27
JP2000516634A (ja) 2000-12-12
KR20000036225A (ko) 2000-06-26
OA10996A (en) 2001-11-06
US6313302B2 (en) 2001-11-06
JP3195368B2 (ja) 2001-08-06
IL128959A0 (en) 2000-02-17
AU719895B2 (en) 2000-05-18
DE69724805T2 (de) 2004-07-01
UA60310C2 (uk) 2003-10-15
NO991294D0 (no) 1999-03-17
CO4920224A1 (es) 2000-05-29
JP2001316344A (ja) 2001-11-13
CA2266006A1 (fr) 1998-03-26
AP9701082A0 (en) 1997-10-31
AR008168A1 (es) 1999-12-09
US20010020024A1 (en) 2001-09-06
TNSN97092A1 (ar) 1999-12-31
ATE249433T1 (de) 2003-09-15
US20010014683A1 (en) 2001-08-16
EP0934264B1 (fr) 2003-09-10
EA001341B1 (ru) 2001-02-26
US20010008890A1 (en) 2001-07-19
KR100339666B1 (ko) 2002-06-05
US6201007B1 (en) 2001-03-13
DE69724805D1 (de) 2003-10-16
NO991294L (no) 1999-03-17
DZ2309A1 (fr) 2002-12-28
AU3781297A (en) 1998-04-14
TR199900590T2 (xx) 1999-07-21

Similar Documents

Publication Publication Date Title
TNSN97161A1 (fr) Aralkyl-et aralkylidene-lactames et -imides heterocycliques, procedes pour leur preparation et compositions pharmaceutiques les contenant
TNSN97056A1 (fr) Derives de lactames, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98216A1 (fr) Derives d'acide hydrauxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
TNSN97144A1 (fr) Derives 6,6-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99142A1 (fr) Derives de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procede pour leur preparation.
TNSN97190A1 (fr) Derives d'amines bicycliques.
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98203A1 (fr) Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97139A1 (fr) Derives d'acides d'arylsulfonylaminohydroxamiques
TNSN98182A1 (fr) Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26696A1 (fr) Derives de tetrahydrobenzazepine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99039A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97148A1 (fr) Derives d'indazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN96072A1 (fr) N-(indole -2-carbonyl)-glycinamides substitues, procede pour leur preparation et compositions les contenant
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN97193A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97078A1 (fr) Derives d'indole nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
TNSN96075A1 (fr) N-(indole-2-carbonyl) - beta- alaninamides substitues et leurs derives, servant d'agents antidiabetiques
TNSN00104A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97192A1 (fr) Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98154A1 (fr) Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant